The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
What do we know about the reduction of Pt(IV) pro-drugs?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Reedijk, J. (1999) · Chemical Reviews · doi:10.1021/cr980422f · Cited by 771
Takahara, P. M., Rosenzweig, A. C., Frederick, C. A., & Lippard, S. J. (1995) · Nature · doi:10.1038/377649a0 · Cited by 769
Galanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
Mechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
Platinum(IV) antitumour compounds: their bioinorganic chemistry
Hall, M. D., & Hambley, T. W. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00026-7 · Cited by 622
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Fuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Elucidating the hard/soft acid/base principle: A perspective based on half-reactions
Ayers, P. W., Parr, R. G., & Pearson, R. G. (2006) · The Journal of Chemical Physics · doi:10.1063/1.2196882 · Cited by 371
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Michelet, F., Gueguen, R., Leroy, P., Wellman, M., Nicolas, A., & Siest, G. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1509 · Cited by 326
Ang, W. H., Khalaila, I., Allardyce, C. S., Juillerat-Jeanneret, L., & Dyson, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0432618 · Cited by 314
Reduction and Anticancer Activity of Platinum(IV) Complexes
Choi, S., Filotto, C., Bisanzo, M., Delaney, S., Lagasee, D., Whitworth, J. L., Jusko, A., Li, C., Wood, N. A., Willingham, J., et al. (1998) · Inorganic Chemistry · doi:10.1021/ic971047x · Cited by 270
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
Giandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Rheinheimer, M. I., Wyer, S. B., Bossard, G. E., & Higgins, J. D. (1995) · Inorganic Chemistry · doi:10.1021/ic00109a004 · Cited by 248
Lovejoy, K. S., Todd, R. C., Zhang, S., McCormick, M. S., D'Aquino, J. A., Reardon, J. T., Sancar, A., Giacomini, K. M., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803441105 · Cited by 238
Conjugated Platinum(IV)−Peptide Complexes for Targeting Angiogenic Tumor Vasculature
Mukhopadhyay, S., Barnés, C. M., Haskel, A., Short, S. M., Barnes, K. R., & Lippard, S. J. (2008) · Bioconjugate Chemistry · doi:10.1021/bc070031k · Cited by 226
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review
Pinzani, V., Bressolle, F., Johanne Haug, I., Galtier, M., Blayac, J. P., & Balm�s, P. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686277 · Cited by 217
Clinical Pharmacokinetics and Administration of Established Platinum Drugs
O??Dwyer, P. J., Stevenson, J. P., & Johnson, S. W. (2000) · Drugs · doi:10.2165/00003495-200059004-00003 · Cited by 217
How do real tumors become resistant to cisplatin?
Borst, P., Rottenberg, S., & Jonkers, J. (2008) · Cell Cycle · doi:10.4161/cc.7.10.5930 · Cited by 192
Zhang, J. Z., Wexselblatt, E., Hambley, T. W., & Gibson, D. (2012) · Chem. Commun. · doi:10.1039/c1cc16647f · Cited by 190
Self-citationPt(IV) complexes as prodrugs for cisplatin
Shi, Y., Liu, S.-A., Kerwood, D. J., Goodisman, J., & Dabrowiak, J. C. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.10.012 · Cited by 179
Berners-Price, S. J., Ronconi, L., & Sadler, P. J. (2006) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2006.05.002 · Cited by 176
Hall, M. D., Dillon, C. T., Zhang, M., Beale, P. J., Cai, Z., Lai, B. C. H., Stampfl, A. P. J., & Hambley, T. W. (2003) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-003-0471-6 · Cited by 157
Kasherman, Y., Stürup, S., & Gibson, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900138u · Cited by 152
Self-citationHall, M. D., Foran, G. J., Zhang, M., Beale, P. J., & Hambley, T. W. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0354770 · Cited by 140
Reduction ofcis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by Aqueous Extracts of Cancer Cells
Nemirovski, A., Kasherman, Y., Ardeli‐Tzaraf, Y., & Gibson, D. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070740j · Cited by 113
Self-citationReiber, H., Ruff, M., & Uhr, M. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90162-w · Cited by 112
Anderson, H. D., Wagstaff, J. D., Crowther, D., Swindell, R., Lind, M., McGregor, J., Timms, M. S., Brown, D., & Palmer, P. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90338-0 · Cited by 91
Varbanov, H. P., Valiahdi, S. M., Legin, A. A., Jakupec, M. A., Roller, A., Galanski, M. S., & Keppler, B. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.09.006 · Cited by 84
Chen, H., Song, I., Hossain, A., Choi, M., YAMANE, Y., Zheng, L., Lu, J., Wu, L. Y. H., Siddik, Z. H., Klomp, L. W. J., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047969 · Cited by 80
Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity
Chin, C. F., Wong, D. Y. Q., Jothibasu, R., & Ang, W. H. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611798040778 · Cited by 80
Ascorbic acid in human neutrophils
Washko, P., Rotrosen, D., & Levine, M. (1991) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.6.1221s · Cited by 78
Hah, S. S., Sumbad, R. A., White, R. D., Turteltaub, K. W., & Henderson, P. T. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700376a · Cited by 69
Genotoxic Mechanism of Tamoxifen in Developing Endometrial Cancer
Kim, S. Y., Suzuki, N., Laxmi, Y. R. S., & Shibutani, S. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120033997 · Cited by 56
Reithofer, M. R., Valiahdi, S. M., Galanski, M. S., Jakupec, M. A., Arion, V. B., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890197 · Cited by 41
Boubakari, Bracht, K., Neumann, C., et al. (2004) · Archiv der Pharmazie · doi:10.1002/ardp.200400620 · Cited by 27
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2014) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 630
Metal-based anticancer chemotherapeutic agents
Muhammad, N., & Guo, Z. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.02.003 · Cited by 515
Metadata
- Authors
- Wexselblatt, E., & Gibson, D.
- Venue
- Journal of Inorganic Biochemistry
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 117
- Pages
- 220-229
- ISSN
- 0162-0134 (ISSN-L)
- OpenAlex
- W2027901828
- Cited by
- 370
- References
- 47
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.